Better response to chemotherapy and prolonged survival in aids-related lymphomas responding to highly active antiretroviral therapy

AIDS

Volumn 15, Issue 12, 2001, Pages 1483-1491

  Antinori, Andrea ^a   Cingolani, Antonella ^b   Alba, Lucia ^a   Ammassari, Adriana ^b   Serraino, Diego ^a   Ciancio, Bruno C ^b   Palmieri, Fabrizio ^a   De Luca, Andrea ^b   Larocca, Luigi M ^b   Ruco, Luigi ^a   Ippolito, Giuseppe ^a   Cauda, Roberto ^b  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

AIDS; Antiretroviral therapy; Cancers; Chemotherapy; Combination therapy; HAART; HIV; Non Hodgkin's lymphoma

Indexed keywords

ABACAVIR; ACICLOVIR; ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; BLEOMYCIN; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DAUNORUBICIN DERIVATIVE; DEXAMETHASONE; DIDANOSINE; DOXORUBICIN; EFAVIRENZ; FLUCONAZOLE; HYDROXYDAUNORUBICIN; INDINAVIR; LAMIVUDINE; METHOTREXATE; NELFINAVIR; NEVIRAPINE; PREDNISONE; PROTEINASE INHIBITOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE SULFATE; ZIDOVUDINE;

ADULT; AIDS RELATED COMPLEX; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; ITALY; LYMPHOMA; MALE; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; RISK ASSESSMENT; SURVIVAL RATE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOMA, AIDS-RELATED; LYMPHOMA, NON-HODGKIN; MALE; PROSPECTIVE STUDIES; RNA, VIRAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0035902947     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200108170-00005     Document Type: Article

References (32)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
2. Altered natural history of AIDS-related opportunistic infections in the era of potent combination antiretroviral therapy
3. Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1-infected individuals
4. Kaposi's sarcoma and non-Hodgkin's lymphoma incidence trends in AIDS Clinical Trial Group Study participants
5. Effect of antiretroviral therapy on recent trends in selected cancers among HIV-infected persons
6. Combination antiretroviral therapy and incidence of AIDS-related malignancies
7. Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: Prospective cohort study
8. Changes in acquired immunodeficiency syndrome related lymphoma since the introduction of highly active antiretroviral therapy
9. HIV-associated non-Hodgkin's lymphoma: Highly active antiretroviral therapy improves remission rate of chemotherapy
10. Prognostic factors after non-Hodgkin's lymphoma in patients infected with the human immunodeficiency virus: Aquitaine cohort, France, 1986-1997
11. Quantitative and cost comparison of ultrasensitive human immunodeficiency virus type 1 RNA viral load assays: Bayer bDNA Quantiplex versions 3.0 and 2.0 and Roche PCR Amplicor Monitor Version 1.5
12. Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: Analysis of AIDS Clinical Trials Group protocol 142 - Low dose versus standard m-BACOD plus granulocyte-macrophage colony-stimulating factor
13. Treatment of HIV-related non-Hodgkin's lymphoma adapted to prognostic factors
14. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
15. Human immunodeficiency virus-related lymphoma treatment with intensive combination chemotherapy
16. Clinical and virologic effects of recombinant human granulocyte macrophage colony stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: Results of a randomized trial
17. Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma
18. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection
19. Second-line chemotherapy in human immunodeficiency virus-related non-Hodgkin's lymphoma: Evidence of activity of a combination of etoposide, mitoxantrone, and prednimustine in relapsed patients
20. Antiretroviral therapy in adults. Updated recommendations of the International AIDS Society - USA Panel
21. The importance of dose intensity chemotherapy of metastatic breast cancer
22. The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin's lymphoma
23. The analysis of case-control studies
24. Non-parametric estimation from incomplete observations
25. AIDS-associated non-Hodgkin's lymphomas in San Francisco
26. Human immunodeficiency virus-related lymphoma
27. Dose-adjusted EPOCH chemotherapy in previously untreated HIV-associated non-Hodgkin's lymphoma: Preliminary report of efficacy, immune reconstitution, and HIV control following therapy
28. Prospective study with combined low-dose chemotherapy and zidovudine in 37 patients with poor prognosis AIDS-related non-Hodgkin's lymphoma
29. Concomitant CHOP chemotherapy and highly active antiretroviral therapy in patients with HIV-related non-Hodgkin's lymphoma
30. Opportunistic infection and immunologic function in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma treated with chemotherapy